Kailera Therapeutics, Inc. KLRA
Kailera Therapeutics, Inc. (Nasdaq: KLRA) is a cardio-renal-metabolic drug developer. Its lead program, ribupatide injection (KAI-9531), is in Phase 3 for obesity / overweight. Its next catalyst on record is ribupatide oral: Initiate global Phase 3 trials (H1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: ribupatide oral — Initiate global Phase 3 trials (H1 2027). 6 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ribupatide injection (KAI-9531), once-weekly GLP-1/GIP dual agonist | obesity or overweight | protein/peptide | Phase 3 |
| ribupatide oral (KAI-9531-T) | obesity | protein/peptide | Phase 2 |
| KAI-7535 | obesity | small molecule | Phase 2 |
| KAI-4729 | obesity | protein/peptide | Phase 1 |
Recent results and decisions
- Aug 12, 2026met Hengrui Phase 3 in T2D: significant HbA1c reductions vs placebo, max mean reduction 2.67%.
once-weekly ribupatide injection (4 mg and 2 mg) vs. placebo showed significant reductions in HbA1c from baseline, with a maximum mean reduction of 2.67%, based on the efficacy estimand1
Filing - Aug 12, 2026positive Hengrui Phase 2 in obesity with PMOS: mean weight loss up to 21.2% at Week 32 with no plateau.
once-weekly ribupatide injection (4 mg, 2 mg, or 1 mg) vs. placebo demonstrated a mean weight loss of up to 21.2% based on the efficacy estimand3 with no plateau at Week 32.
Filing - Aug 12, 2026positive Hengrui Phase 3 HARBOR-1: mean weight loss up to 11.1% at Week 50 with 180 mg (ad hoc analysis, efficacy estimand).
participants taking HRS-7535 180 mg achieved a mean weight loss of up to 11.1% from baseline at Week 50, based on an ad hoc analysis under the efficacy estimand3.
Filing
6 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.